TOP2A and neoplasm: Selumetinib resistant tumor cells (C0), defined as the single cell cluster that was enriched in allografts after selumetinib treatment compared to vehicle control, showed reduced expression of cell proliferation genes compared to proliferating tumor cells (C1, Mki67, Top2a) and decreased expression of cell differentiation markers (C2, Mgp, Postn, Pdgfra) and Suz12 in selumetinib resistant cells (Fig. 2d, e and Supplementary Fig. 7b).